CD-19 Antibody Global Market Report 2025

Description

CD19 antibody is a monoclonal antibody that specifically targets the CD19 protein, a cell surface marker primarily found on B cells. CD19 plays a crucial role in B cell development and is often overexpressed in B cell-related malignancies, including certain leukemias and lymphomas. These antibodies are widely used in immunotherapy, particularly in CAR-T cell therapy, to direct the immune system to attack CD19-expressing cancer cells.

The primary disease types in the CD19 antibody market include B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and others. B-cell non-Hodgkin lymphoma originates in B lymphocytes, a type of white blood cell essential for immune defense. CD19 antibodies are classified into polyclonal and monoclonal types, with routes of administration including intravenous and subcutaneous delivery. Their applications span enzyme-linked immunosorbent assay (ELISA), flow cytometry, immunohistochemistry frozen, immunohistochemistry paraffin, and other diagnostic and research uses.

The CD-19 antibody market research report is one of a series of new reports from The Business Research Company that provides CD-19 antibody market statistics, including CD-19 antibody industry global market size, regional shares, competitors with a CD-19 antibody market share, detailed CD-19 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the CD-19 antibody industry. This CD-19 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The CD-19 antibody market size has grown strongly in recent years. It will grow from $1.75 billion in 2024 to $1.91 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the rising prevalence of B-cell malignancies, the increasing adoption of immunotherapy, greater oncology research funding, the emergence of CAR-T cell therapies, heightened healthcare awareness, and the expansion of personalized medicine.

The CD-19 antibody market size is expected to see strong growth in the next few years. It will grow to $2.70 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth during the forecast period is driven by the increasing demand for targeted cancer therapies, the rising adoption of smart cell therapies, a higher prevalence of hematologic malignancies, expanded healthcare access in emerging markets, as well as the development of next-generation immunotherapies and enhancements in biomanufacturing technologies. Key trends in this period include advancements in antibody-drug conjugates, the development of bispecific antibodies, the integration of AI into antibody design, improvements in cell-cell therapy platforms, the adoption of single-use bioreactors, the emergence of nanobody-based therapeutics, and the automation of biologics manufacturing.

The increasing prevalence of B-cell malignancies is expected to drive the growth of the CD19 antibody market. B-cell malignancies encompass a group of cancers originating from abnormal B lymphocytes, such as B-cell lymphomas and leukemias, which affect the immune system and lead to uncontrolled cell growth. Several factors contribute to the rising prevalence of these malignancies, including aging populations, genetic predisposition, environmental exposures, lifestyle changes, advancements in detection methods, and immune system alterations. CD19 antibodies play a crucial role in treating B-cell malignancies by specifically targeting the CD19 protein found on malignant B cells, effectively destroying them while sparing healthy cells and boosting the immune response. For example, in January 2024, the American Cancer Society reported that approximately 80,620 people in the U.S. were expected to be diagnosed with non-Hodgkin lymphoma, with an estimated 20,240 deaths. As a result, the growing incidence of B-cell malignancies is fueling the expansion of the CD19 antibody market.

Leading companies in the CD19 antibody market are focusing on technological innovations, such as genetically modified autologous T-cell immunotherapy, to improve cancer treatment effectiveness, particularly for hematologic malignancies. This therapy involves genetically engineering a patient's T cells to recognize and attack cancer cells before reintroducing them into the body to enhance immune response. For instance, in November 2024, Autolus Therapeutics plc, a U.S.-based biopharmaceutical company, received FDA approval for AUCATZYL (obecabtagene autoleucel) for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The treatment is designed to minimize toxicity and improve the persistence of therapeutic cells through controlled T-cell activation. It is administered as a split-dose infusion on days 1 and 10, with dosing tailored to individual patient needs based on bone marrow assessment.

In December 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired Gracell Biotechnologies Inc. to strengthen its cell therapy pipeline. The acquisition aims to leverage Gracell Biotechnologies' innovative FasTCAR platform and expertise in developing CD19 and BCMA-targeted CAR-T therapies. Gracell Biotechnologies Inc., a China-based clinical-stage biopharmaceutical company, focuses on discovering and developing cutting-edge cell therapies, reinforcing AstraZeneca's commitment to advancing cancer treatment options.

Major players in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in CD-19 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the CD-19 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CD-19 antibody market consists of revenues earned by entities by providing monoclonal antibody therapies, CAR-T cell therapies, diagnostic services, biopharmaceutical research and development, and manufacturing services related to the production of CD-19 targeted treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD-19 antibody market includes the sale of recombinant antibodies, and antibody-based therapies targeting CD19 for research and clinical applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CD-19 Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cd-19 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cd-19 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cd-19 antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types
2) By Type: Polyclonal, Monoclonal
3) By Route Of Administration: Intravenous, Subcutaneous
4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications
Subsegments:
1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Mantle Cell Lymphoma
2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL; Treatment-Naive CLL
3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL; Philadelphia Chromosome-Positive ALL
4) By Other Disease Types: Hairy Cell Leukemia; Waldenstrom's Macroglobulinemia; Marginal Zone Lymphoma
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AstraZeneca plc; Novartis AG; Thermo Fisher Scientific Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33996

1. Executive Summary

2. CD-19 Antibody Market Characteristics

3. CD-19 Antibody Market Trends And Strategies

4. CD-19 Antibody Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global CD-19 Antibody Growth Analysis And Strategic Analysis Framework

5.1. Global CD-19 Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global CD-19 Antibody Market Growth Rate Analysis
5.4. Global CD-19 Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global CD-19 Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global CD-19 Antibody Total Addressable Market (TAM)

6. CD-19 Antibody Market Segmentation

6.1. Global CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
B-Cell Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Other Disease Types
6.2. Global CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Polyclonal
Monoclonal
6.3. Global CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Subcutaneous
6.4. Global CD-19 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Linked Immunosorbent Assay
Flow Cytometry
Immunohistochemistry Frozen
Immunohistochemistry Paraffin
Other Applications
6.5. Global CD-19 Antibody Market, Sub-Segmentation Of B-Cell Non-Hodgkin Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diffuse Large B-Cell Lymphoma (DLBCL)
Follicular Lymphoma
Mantle Cell Lymphoma
6.6. Global CD-19 Antibody Market, Sub-Segmentation Of Chronic Lymphocytic Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Relapsed Or Refractory CLL
Treatment-Naive CLL
6.7. Global CD-19 Antibody Market, Sub-Segmentation Of Acute Lymphoblastic Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
B-Cell Precursor ALL
Philadelphia Chromosome-Positive ALL
6.8. Global CD-19 Antibody Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hairy Cell Leukemia
Waldenstrom's Macroglobulinemia
Marginal Zone Lymphoma

7. CD-19 Antibody Market Regional And Country Analysis

7.1. Global CD-19 Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global CD-19 Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific CD-19 Antibody Market

8.1. Asia-Pacific CD-19 Antibody Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China CD-19 Antibody Market

9.1. China CD-19 Antibody Market Overview
9.2. China CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India CD-19 Antibody Market

10.1. India CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan CD-19 Antibody Market

11.1. Japan CD-19 Antibody Market Overview
11.2. Japan CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia CD-19 Antibody Market

12.1. Australia CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia CD-19 Antibody Market

13.1. Indonesia CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea CD-19 Antibody Market

14.1. South Korea CD-19 Antibody Market Overview
14.2. South Korea CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe CD-19 Antibody Market

15.1. Western Europe CD-19 Antibody Market Overview
15.2. Western Europe CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK CD-19 Antibody Market

16.1. UK CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany CD-19 Antibody Market

17.1. Germany CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France CD-19 Antibody Market

18.1. France CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy CD-19 Antibody Market

19.1. Italy CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain CD-19 Antibody Market

20.1. Spain CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe CD-19 Antibody Market

21.1. Eastern Europe CD-19 Antibody Market Overview
21.2. Eastern Europe CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia CD-19 Antibody Market

22.1. Russia CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America CD-19 Antibody Market

23.1. North America CD-19 Antibody Market Overview
23.2. North America CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA CD-19 Antibody Market

24.1. USA CD-19 Antibody Market Overview
24.2. USA CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada CD-19 Antibody Market

25.1. Canada CD-19 Antibody Market Overview
25.2. Canada CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America CD-19 Antibody Market

26.1. South America CD-19 Antibody Market Overview
26.2. South America CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil CD-19 Antibody Market

27.1. Brazil CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East CD-19 Antibody Market

28.1. Middle East CD-19 Antibody Market Overview
28.2. Middle East CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa CD-19 Antibody Market

29.1. Africa CD-19 Antibody Market Overview
29.2. Africa CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. CD-19 Antibody Market Competitive Landscape And Company Profiles

30.1. CD-19 Antibody Market Competitive Landscape
30.2. CD-19 Antibody Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

31. CD-19 Antibody Market Other Major And Innovative Companies

31.1. Amgen Inc.
31.2. Bio-Rad Laboratories Inc.
31.3. Miltenyi Biotec GmbH
31.4. Abcam Plc
31.5. Kite Pharma Inc.
31.6. BioLegend Inc.
31.7. Xencor Inc.
31.8. Juno Therapeutics Inc.
31.9. BD Biosciences
31.10. Zenas BioPharma Inc.
31.11. Cell Signaling Technology Inc.
31.12. Santa Cruz Biotechnology Inc.
31.13. Novus Biologicals LLC
31.14. Tonbo Biosciences Inc.
31.15. Bio X Cell Inc.

32. Global CD-19 Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The CD-19 Antibody Market

34. Recent Developments In The CD-19 Antibody Market

35. CD-19 Antibody Market High Potential Countries, Segments and Strategies

35.1 CD-19 Antibody Market In 2029 - Countries Offering Most New Opportunities
35.2 CD-19 Antibody Market In 2029 - Segments Offering Most New Opportunities
35.3 CD-19 Antibody Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer